Skip to main content
. 2013 Sep 24;8(9):e75894. doi: 10.1371/journal.pone.0075894

Figure 9. GFP mRNA and protein in heart and liver after treatment with the pAUSiGrLuc vector.

Figure 9

To address the question of whether the cardiac troponin T promoter in the pAUSiGTL vector might contribute to cardiac-selective knockdown, we tested the pAUSiGrLuc vector which contained luciferase without the cTnT promoter. (A) GAPDH-normalized mRNA shows an 82% reduction compared to an untreated control group in the heart (n=5-8/group, p<0.0001) and a 36% reduction in GFP mRNA compared to controls in the liver (n=5-8/group, p<0.01). (B) Western blot analysis showed that GAPDH-normalized GFP expression was reduced by 51% in the shGFP-treated group compared to controls in heart (n=4/group, p<0.0001), with no difference in GFP expression between groups in the liver.